Esperion Therapeutics, Inc. ( ESPR - Free Report ) incurred a loss of $2.26 per share in the fourth quarter of 2019, narrower than the Zacks Consensus Estimate of $2.71. The company had incurred loss of $2.24 per share in the year-ago period.